ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)
- Resource Type
- Article
- Source
- In
Lung Cancer March 2022 165:54-62 - Subject
- Language
- ISSN
- 0169-5002